Department of clinical pharmacy, Faculty of pharmacy, Tabriz University of Medical Sciences, Tabriz, 5166414766, Iran.
Future Microbiol. 2022 Mar;17(5):377-391. doi: 10.2217/fmb-2021-0252. Epub 2022 Feb 24.
Despite the progress in the management of COVID-19, effective oral antiviral agents are still lacking. In the present review, the potential beneficial effects of molnupiravir in the management of COVID-19 are discussed. A literature search in Google Scholar, Scopus, PubMed and clinicaltrials.gov for the relevant articles regarding the pharmacokinetics, pharmacodynamics and clinical trials of molnupiravir in the management of COVID-19 is conducted. Most of the preclinical studies and available clinical trials showed a favorable short-term safety profile of molnupiravir; however, given its possible genotoxic effects, further trials are required to confirm the long-term efficacy and safety of molnupiravir in patients with COVID-19.
尽管在 COVID-19 的管理方面取得了进展，但仍然缺乏有效的口服抗病毒药物。在本综述中，讨论了莫努匹韦在 COVID-19 管理中的潜在有益作用。在 Google Scholar、Scopus、PubMed 和 clinicaltrials.gov 上进行了针对莫努匹韦在 COVID-19 管理中的药代动力学、药效学和临床试验的相关文章的文献检索。大多数临床前研究和现有临床试验显示，莫努匹韦具有良好的短期安全性；然而，鉴于其可能的遗传毒性作用，需要进一步的试验来证实莫努匹韦在 COVID-19 患者中的长期疗效和安全性。
